NVNO · NASDAQ
enVVeno Medical Corporation
$6.81 -0.24 (-3.40%)
Company overview
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of chronic venous insufficiency. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $4.7M
- Employees
- 37
- Headquarters
- Irvine, CA
- Website
- envveno.com
- CEO
- Robert A. Berman
- Listed
- May 31, 2018
- P/E
- -0.01
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$491,000
- Operating income
- -$20M
- EBITDA
- -$19.5M
- Net income
- -$18.8M
- EPS
- -$697.80
- Total assets
- $26.1M
- Total debt
- $603,000
- Earnings yield
- -10,246.70%
NVNO
1D
NASDAQ
O7.04H7.34L6.96C7.05+0.30 (+4.52%)Vol5.91K